As President and CEO of Harmony Biosciences, Dr. Jeffrey M. Dayno holds 125,000 options in the company, reflecting a strong ownership stake. The options he received, valued at about $3.5 million based on current figures, profile his commitment to the...
As President and CEO of Harmony Biosciences, Dr. Jeffrey M. Dayno holds 125,000 options in the company, reflecting a strong ownership stake. The options he received, valued at about $3.5 million based on current figures, profile his commitment to the company’s success. His significant equity means that a large part of his potential wealth is tied to Harmony’s performance, encouraging alignment with shareholder interests. Early in his appointment, he also secured a retention bonus of $200,000. Over time, Dr. Dayno has navigated fluctuations in his wealth, primarily tied to company growth and product revenues. Harmony's performance under his leadership showcased robust revenue which indicates a strong potential for growth in future valuations. His financial interests are tightly aligned with the direction and health of the company he leads.